Authors Posts by BiotechBlog

BiotechBlog

3307 POSTS 0 COMMENTS

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Current and future prospects for the global biotechnology industry

Go to paper

ABSTRACT: The number of biotechnology compounds has been increasing steadily over the past 20 years, reflecting the key contribution that biotechnology is now making to healthcare. Recombinant DNA technology has been used to develop a number of therapeutic proteins, including antibodies, cytokines, hormones and vaccines for use in tackling and diagnosing a range of disorders...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

Drug Patent Expirations for April 2015

Tradename Applicant Generic Name Patent Number Patent Expiration
FAMVIR Novartis famciclovir 5,866,581*PED Apr 4, 2015
FAMVIR Novartis famciclovir 6,124,304*PED Apr 4, 2015
PROVIGIL Cephalon modafinil RE37516*PED Apr 6, 2015
NUVIGIL Cephalon armodafinil RE37516*PED Apr 6, 2015
ADVAIR HFA Glaxo Grp Ltd fluticasone propionate; salmeterol xinafoate 5,674,472*PED Apr 7, 2015
HYCAMTIN Glaxosmithkline topotecan hydrochloride 5,674,872*PED Apr 7, 2015
FLOVENT HFA Glaxo Grp Ltd fluticasone propionate 5,674,472*PED Apr 7, 2015
AKYNZEO Helsinn Hlthcare netupitant; palonosetron hydrochloride 5,202,333 Apr 13, 2015
ALOXI Helsinn Hlthcare palonosetron hydrochloride 5,202,333 Apr 13, 2015
MYLOTARG Wyeth Pharms Inc gemtuzumab ozogamicin 5,739,116 Apr 14, 2015
GATTEX KIT Nps Pharms Inc teduglutide recombinant 5,789,379 Apr 14, 2015
CLEVIPREX Medicines Co clevidipine 5,739,152 Apr 14, 2015
JUXTAPID Aegerion lomitapide mesylate 5,739,135 Apr 14, 2015
EMEND Merck aprepitant 5,719,147 Apr 17, 2015
ABILIFY MAINTENA KIT Otsuka Pharm Co Ltd aripiprazole 5,006,528 Apr 20, 2015
ABILIFY Otsuka aripiprazole 5,006,528*PED Apr 20, 2015
CAVERJECT Pharmacia And Upjohn alprostadil 5,741,523 Apr 21, 2015
EXUBERA Pfizer insulin recombinant human 5,740,794 Apr 21, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,601,839 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,601,839 Apr 26, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,834,010 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,834,010 Apr 26, 2015
MAVIK Abbvie trandolapril 5,744,496 Apr 28, 2015
LAMISIL AT Novartis terbinafine 5,681,849*PED Apr 28, 2015
LAMISIL AT Novartis terbinafine hydrochloride 5,681,849*PED Apr 28, 2015
LAMISIL Novartis terbinafine 5,681,849*PED Apr 28, 2015
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Drug Patent Expirations for April 2015

Tradename Applicant Generic Name Patent Number Patent Expiration
FAMVIR Novartis famciclovir 6,124,304*PED Apr 4, 2015
FAMVIR Novartis famciclovir 5,866,581*PED Apr 4, 2015
PROVIGIL Cephalon modafinil RE37516*PED Apr 6, 2015
NUVIGIL Cephalon armodafinil RE37516*PED Apr 6, 2015
ADVAIR HFA Glaxo Grp Ltd fluticasone propionate; salmeterol xinafoate 5,674,472*PED Apr 7, 2015
HYCAMTIN Glaxosmithkline topotecan hydrochloride 5,674,872*PED Apr 7, 2015
FLOVENT HFA Glaxo Grp Ltd fluticasone propionate 5,674,472*PED Apr 7, 2015
AKYNZEO Helsinn Hlthcare netupitant; palonosetron hydrochloride 5,202,333 Apr 13, 2015
ALOXI Helsinn Hlthcare palonosetron hydrochloride 5,202,333 Apr 13, 2015
JUXTAPID Aegerion lomitapide mesylate 5,739,135 Apr 14, 2015
MYLOTARG Wyeth Pharms Inc gemtuzumab ozogamicin 5,739,116 Apr 14, 2015
GATTEX KIT Nps Pharms Inc teduglutide recombinant 5,789,379 Apr 14, 2015
CLEVIPREX Medicines Co clevidipine 5,739,152 Apr 14, 2015
EMEND Merck aprepitant 5,719,147 Apr 17, 2015
ABILIFY MAINTENA KIT Otsuka Pharm Co Ltd aripiprazole 5,006,528 Apr 20, 2015
ABILIFY Otsuka aripiprazole 5,006,528*PED Apr 20, 2015
CAVERJECT Pharmacia And Upjohn alprostadil 5,741,523 Apr 21, 2015
EXUBERA Pfizer insulin recombinant human 5,740,794 Apr 21, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,601,839 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,601,839 Apr 26, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,834,010 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,834,010 Apr 26, 2015
LAMISIL Novartis terbinafine 5,681,849*PED Apr 28, 2015
MAVIK Abbvie trandolapril 5,744,496 Apr 28, 2015
LAMISIL AT Novartis terbinafine 5,681,849*PED Apr 28, 2015
LAMISIL AT Novartis terbinafine hydrochloride 5,681,849*PED Apr 28, 2015
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Building biotechnology teams: Personality does matter

Go to paper

ABSTRACT: Our study describes a naturally occurring experiment exploring linkages between interdisciplinary team outcomes and personality dimensions, general mental ability, and communication type and frequency. This research took place within the context of an NSF-sponsored bioscience entrepreneurship program that engaged science, health science, law and business students working in cross-disciplinary project teams in the technology commercialization process...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for April 4 2015

TradenameApplicantGeneric NamePatent Expiration
FAMVIR
Novartis
famciclovir
Apr 4, 2015

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


Instant Access to Deep Knowledge on Small-Molecule Drugs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent data
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Formulation
  • Suppliers
  • Dynamic search capabilities with data export
  • More…

More than 6,400 small-molecule drugs from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 80,000 U.S. and international patents.

See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

The field of bioinformatics is flourishing, and strong growth is only projected to continue. Like any cutting edge technology, bioinformatics requires an integrated IP strategy involving patent, trade secret, and copyright laws. The patent system in particular can be a powerful protection for commercializing bioinformatics inventions as long as a corresponding patent application meets certain patent law standards. Recently, the most rapidly evolving of these patent law standards—patent eligibility—came to a crescendo last year when the Supreme Court in Alice v. CLS Bank introduced a two-step test for determining whether computer-implemented inventions are patent-eligible. Since then, other courts and the USPTO have applied the test on inventions implemented on a computer and/or using the Internet with fact-dependent results. Here, we discuss how these decisions relate to bioinformatics inventions. We then analyze bioinformatics patents that have recently issued post-Alice. While the law remains relatively underdeveloped, it becomes clear that relying on a general purpose computer to perform routine or conventional steps in a claim will not infuse patent-eligibility into a claim. However, bioinformatics inventions remain patentable, especially when the patent prosecution team properly and persuasively presents the technical improvements and commercial embodiments.

After dominating the world tea market since last 170 years, today India became the fourth largest tea exporter. The state Assam, located in the Northeastern end of the country contributes almost 50% of the India’s total tea production and Small tea growers of Assam (STGs) produces around 30% of its total annual production and contributes almost 12% of India’s annual production. Though the use of harmful pesticides and fertilizers by the STGs of Assam is still not recognized and controversial in the state, but it is observed that STGs of Assam hardly follows standard scientific techniques for handling such chemicals. Therefore, maintenance of sound health of STGs and environmental safety is a necessary issue. But, till date no such awareness program was found to be initiated scientifically to teach them about those safety measures. Therefore, there is a great need for immediate implementation of such kind of scientific solutions, basically for storing (micro level) of these harmful chemicals and also for grass root level safety campaign by scientific communities of India including other competent Agencies. 

As a small biotech company embarks on a drug development program, there is a tendency for management to focus on a well-defined set of issues. Is the science behind the drug valid? Does it solve an interesting problem or unmet need? What are the prospects that the medical community and patients will embrace it as a valuable new solution? And what is the range of indications the drug is conceived as addressing? These are all valid questions, but a small biotech can do even more to prepare itself for the drug development process, which is a journey that can take many years and cost a significant amount of money. 

America deserves access to high-quality health care without avoidable medical errors and complications. This achievable goal begins with harnessing and using the power of information. And that begins with clear, accurate, and usable labeling.

The American health care system is undermined, underserved, and undervalued when labeling is written more for corporate liability protection than as a valuable tool for health care providers.

Today, labeling includes excessive risk information and exaggerated warnings. And this has set into motion a dangerous dynamic: labeling that does not accurately communicate to either the health care professional or the patient the conditions in which any given product can be used safely and effectively. This is nothing less than a grave menace to the public health. America is suffering from a legal system that is dangerous to its health. Why has this happened? There is, unfortunately, a simple answer - fear of liability. Manufacturers have significant monetary incentives to add dense and confusing legalese because, under current law in most states, they can be found liable for failing to provide "adequate" warnings about therapeutic products. Money, not medicine, is driving this dangerous practice. When it comes to labeling written for lawyers rather than doctors, more is less.

Historically, innovation in the biotechnology sector has relied to a large extent on the expensive infrastructure provided by universities or large pharmaceutical companies. This prohibitive start-up expense is the basis of why garage-style biotechnology entrepreneurs are exceedingly rare as compared to their software and high-tech counterparts. Recent consolidation among pharmaceutical companies and the release of next generation research equipment has produced an affordable surplus in the secondary equipment markets, reducing the barrier to entry posed by equipment expenses. We examine the biotechnology start-up Ichor Therapeutics, Inc., and review strategies that the founding team has successfully employed to establish an affordable laboratory, reduce research expenses, and promote communication among team members.